Interfocal heterogeneity challenges the clinical usefulness of molecular classification of primary prostate cancer.

ABSTRACT: Prostate cancer is a highly heterogeneous disease and typically multiple distinct cancer foci are present at primary diagnosis. Molecular classification of prostate cancer can potentially aid the precision of diagnosis and treatment. A promising genomic classifier was published by The Cancer Genome Atlas (TCGA), successfully classifying 74% of primary prostate cancers into seven groups based on one cancer sample per patient. Here, we explore the clinical usefulness of this classification by testing the classifier's performance in a multifocal context. We analyzed 106 cancer samples from 85 distinct cancer foci within 39 patients. By somatic mutation data from whole-exome sequencing and targeted qualitative and quantitative gene expression assays, 31% of the patients were uniquely classifie

SUBMITTER: Carm KT 

PROVIDER: S-EPMC6753093 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature